Evidence map›Paper›PMID 29353652›Full record

ArticleInternational journal of radiation oncology, biology, physics2018

Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma.

Issam El Naqa, Adam Johansson, Dawn Owen, Kyle Cuneo, Yue Cao, Martha Matuszak, Latifa Bazzi, Theodore S Lawrence, Randall K Ten Haken

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Improved outcome models with denoising diffusion.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Issam El NaqaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Adam JohanssonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Dawn OwenDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Kyle CuneoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Yue CaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Martha MatuszakDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Latifa BazziDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Randall K Ten HakenDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: rth@med.umich.edu.
University of Michigan · US

Funding

TREATMENT VERIFICATION AND TREATMENT PLAN REFINEMENTP01CA059827 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KESSLER, MARC LEWIS, LAWRENCE, THEODORE S · 1993 to 2018
$37.9M
Predicting Liver Function After IrradiationR01CA132834 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CAO, YUE · 2010 to 2015
$1.7M
NCI NIH HHS P01 CA059827NCI NIH HHS R01 CA132834
6 · The paper itself

Abstract

purposeTo develop normal tissue complications (NTCP) models for hepatocellular cancer (HCC) patients who undergo liver radiation therapy (RT) and to evaluate the potential role of functional imaging and measurement of blood-based circulating biological markers before and during RT to improve the performance of these models. METHODS AND MATERIALS: The data from 192 HCC patients who had undergone RT from 2005 to 2014 were evaluated. Of the 192 patients, 146 had received stereotactic body RT (SBRT) and 46 had received conventional RT to a median physical tumor dose of 49.8 Gy and 50.4 Gy, respectively. The physical doses were converted into 2-Gy equivalents for analysis. Two approaches were investigated for modeling NTCP: (1) a generalized Lyman-Kutcher-Burman model; and (2) a generalization of the parallel architecture model. Three clinical endpoints were considered: the change in albumin-bilirubin (ALBI), change in Child-Pugh (C-P) score, and grade ≥3 liver enzymatic changes. Local dynamic contrast-enhanced magnetic resonance imaging portal venous perfusion information was used as an imaging biomarker for local liver function. Four candidate inflammatory cytokines were considered as biological markers. The imaging findings and cytokine levels were incorporated into NTCP modeling, and their role was evaluated using goodness-of-fit metrics.

resultsUsing dosimetric information only, the Lyman-Kutcher-Burman model for the ALBI/C-P change had a steeper response curve compared with grade ≥3 enzymatic changes. Incorporating portal venous perfusion imaging information into the parallel architecture model to represent functional reserve resulted in relatively steeper dose-response curves compared with dose-only models. A larger loss of perfusion function was needed for enzymatic changes compared with ALBI/C-P changes. Increased transforming growth factor-β1 and eotaxin expression increased the trend of expected risk in both NTCP modeling approaches but did not reach statistical significance.

conclusionsThe incorporation of imaging findings and biological markers into NTCP modeling of liver toxicity improved the estimates of expected NTCP risk compared with using dose-only models. In addition, such generalized NTCP models should contribute to a better understanding of the normal tissue response in HCC SBRT patients and facilitate personalized treatment.

Indexed as

AdultAgedBilirubinBiomarkersCarcinoma, HepatocellularChemokine CCL11CytokinesFemaleHumansLiverLiver NeoplasmsMaleMiddle AgedRadiation InjuriesRadiotherapy DosageSerum AlbuminBilirubinBiomarkersChemokine CCL11CytokinesSerum AlbuminTransforming Growth Factor beta1

Identifiers

PMID29353652
PMCPMC5779633
OpenAlexW2781758932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.